Get startedLog in
    Picture of JW (Cayman) Therapeutics Co logo

    2126 — JW (Cayman) Therapeutics Co Cashflow Statement

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapSucker Stock
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for JW (Cayman) Therapeutics Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    2025
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line-702-846-768-591-555
    Depreciation
    Amortisation
    Non-Cash Items34.8231233197337
    Unusual Items
    Other Non-Cash Items
    Changes in Working Capital58.1-9.1236.9-29.859.7
    Change in Accounts Receivable
    Change in Inventories
    Change in Prepaid Expenses
    Change in Other Assets
    Change in Accrued Expenses
    Change in Payable / Accrued Expenses
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities-561-537-398-333-76.8
    Capital Expenditures-137-101-14.6-15.4-1.62
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items0-23.524.500.13
    Sale of Business
    Sale of Fixed Assets
    Other Investing Cash Flow
    Cash from Investing Activities-137-1249.9-15.4-1.49
    Financing Cash Flow Items-18.3-6.79-12.4-12.2-11.6
    Other Financing Cash Flow
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities-30.61120.27590.5-170
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash-796-451-377-249-254